Prepared August 22, 2014

Instructions: Unfortunately, the manuscript system did not allow for Microsoft Excel files as supplementary files, only Microsoft Word. Therefore we have prepared this file to share our underlying dataset. To work with the data below, it may be easiest to select the table below and copy all values into a spreadsheet program e.g. Excel.

Trial ID	ROB element	2012 assessment	2012 rationale
M76001	Random sequence generation (selection bias)	Low	
M76001	Allocation concealment (selection bias)	Low	
M76001	Incomplete outcome data (attrition bias), symptoms	Low	
M76001	Incomplete outcome data (attrition bias), complications of influenza	Unclear	Unclear how complications of influenza were defi
M76001	A159: Incomplete outcome data (attrition bias) safety	Low	
M76001	Safety data	Low	
M76001	A159: Selective reporting (reporting bias)	Low	
M76001	A159: Other bias		
M76001	A159: Blinding of participants and personnel (performance bias)		
M76001	All outcomes	Unclear	Capsule size, but no details of colour or taste or c
M76001	A159: Blinding of outcome assessment (detection bias)		
M76001	All outcomes	Low	
NV16871	Random sequence generation (selection bias)	Low	
NV16871	Allocation concealment (selection bias)	Low	

NV16871	Incomplete outcome data (attrition bias), symptoms	Low	
NV16871	Incomplete outcome data (attrition bias), complications of influenza	Low	
NV16871	A159: Incomplete outcome data (attrition bias)		
NV16871	Safety data	Low	
NV16871	A159: Selective reporting (reporting bias)		
NV16871	A159: Other bias		
NV16871	A159: Blinding of participants and personnel (performance bias)		
NV16871	All outcomes	Unclear	Placebo colour/taste/contents not clear
NV16871	A159: Blinding of outcome assessment (detection bias)		
NV16871	All outcomes	Low	
WP16263	Random sequence generation (selection bias)	Unclear	Unclear risk Described as randomised; procedure
WV15670	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating r "The randomisation numbers were generated by inc., Princeton, NJ, USA)."
WV15670	Allocation concealment (selection bias)	Low	"The investigator telephoned the centre to report The randomization number was then supplied by system (IVRS). The investigator entered the rand
WV15670	Incomplete outcome data (attrition bias), symptoms	High	Available data analyzed by ITTI population and no
WV15670	Incomplete outcome data (attrition bias),	High	Possible effect of oseltamivir on antibody product complications in the infected subpopulation non-

	complications of influenza		
WV15670	Incomplete outcome data (attrition bias), safety data	Low	Based on all participants irrespective of complianc
WV15670	Selective reporting (reporting bias), other bias	High	Outcomes of primary interest for the ITT populati
WV15670	Other bias	Unclear	Placebo contained dehydrocholic acid. Dosage no
WV15670	Blinding of participants and personnel (performance bias), all outcomes	Low	"In order to maintain blinding, each subject had 2 administered from each bottle twice per day at ap the first (day 1) visit Each bottle was labelled with the subject number placebo. Those subjects receiving 75 mg bid recei matching capsule containing placebo from the oth received one capsule containing 75 mg active dru
WV15670	Blinding of outcome assessment (detection bias), all outcomes	Low	"No open key to the randomisation code was avai Roche Headquarters. In the event of a medical em necessary to properly manage the subject, by con The blinding was not required to be broken for an
WV1567	Random sequence	Unclear	Described as randomised; procedure generating

1	generation (selection bias)		randomisations schedule not available "Randomisation was conducted by a central rand The investigator /study coordinator telephoned th the subjects initials, date of birth and smoking his randomisations
WV1567 1	Allocation concealment (selection bias)	Low	number was entered in the appropriate place on the subject's Case Report Form by the in
WV1567 1	Incomplete outcome data (attrition bias), symptoms	Low	Data from study participants without influenza were available for symptom relief
WV1567 1	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody production makes the assessment of influenza status and associated complications in the infected subpopulation non-comparable between the treatment groups
WV1567 1	Incomplete outcome data (attrition bias), safety data	Low	Based on all participants irrespective of compliancewith treatment or infection status
WV1567 1	Selective reporting (reporting bias), other bias	Low	Outcomes of primary interest for the ITT population available in the CONSORT reconstructi
WV1567 1	Other bias	High	Placebo contained dehydrocholic acid Matching placebo used "In order to maintain the double blind nature of the study, subjects received 2 capsules twice daily for all treatments."
WV1567 1	Blinding of participants and personnel (performance bias), all outcomes	Low	"The identification number was added by the investigator at the time of randomisations" "No open key to the code was available at the Study Center..." "The identification number was added by the investigator at the time of randomisations."
WV1567 1	Blinding of outcome assessment (detection bias), all outcomes	Low	"No open key to the code was available at the Study Center, to the Monitors, Statisticians or at Gilead/Roche Headquarters"
WV1567 3 WV1569 7	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating r
WV1567 3 WV1569	Allocation concealment (selection bias)	Unclear	Inadequate information available to ascertain con

7			
WV1567			
3	Incomplete outcome		
WV1569	data (attrition bias),		
7	symptoms	Low	Not applicable to the study design (prophylaxis)
WV1567	Incomplete outcome		
3	data (attrition bias),		
WV1569	complications of		Possible effect of oseltamivir on antibody product
7	influenza	High	complications in the infected subpopulation non-c
WV1567	A159: Incomplete		
3	outcome data (attrition		
WV1569	bias)		
7	Safety data	Low	Based on all randomised participants
WV1567			
3	A159: Selective		
WV1569	reporting (reporting		
7	bias)	Low	Outcomes of primary interest for the ITT populati
WV1567			
3			
WV1569			
7	A159: Other bias	Unclear	Placebo contained dehydrocholic acid. Dosage no
	A159: Blinding of		
WV1567	participants and		
3	personnel (performance		
WV1569	bias)		
7	All outcomes	Unclear	Capsule size, but no details of colour or taste or c
WV1567	A159: Blinding of		
3	outcome assessment		
WV1569	(detection bias)		
7	All outcomes	Unclear	Inadequate information available to ascertain wh
	Random sequence		
WV1570	generation (selection		
7	bias)	Unclear	Described as randomised; procedure generating r
			"Randomization was performed by a central rand
WV1570	Allocation concealment		the subject's date of birth, vaccination status and
7	(selection bias)	Low	randomisation centre."
	Incomplete outcome		
WV1570	data (attrition bias),		
7	symptoms	High	Available data analyzed by ITTI population and no
	Incomplete outcome		
	data (attrition bias),		
WV1570	complications of		Possible effect of oseltamivir on antibody product
7	influenza	High	complications in the infected subpopulation non-c

WV15707	A159: Incomplete outcome data (attrition bias)	Low	Based on all randomised participants
WV15707	A159: Selective reporting (reporting bias)	High	Outcomes of primary interest for the ITT populati
WV15707	A159: Other bias	Unclear	Placebo contained dehydrocholic acid. Dosage no
WV15707	A159: Blinding of participants and personnel (performance bias)	Low	Presentation of placebo described as identical
WV15707	A159: Blinding of outcome assessment (detection bias)	Unclear	Inadequate information available to ascertain wh
WV15708	Random sequence generation (selection bias)	Unclear	Randomization numbers generated by Roche, but
WV15708	Allocation concealment (selection bias)	Unclear	Insufficient details given
WV15708	Incomplete outcome data (attrition bias), symptoms	Low	Outcomes available on all patients who complete
WV15708	Incomplete outcome data (attrition bias), complications of influenza	Low	
WV15708	A159: Incomplete outcome data (attrition bias)	Low	Outcome data on all patients provided.
WV15708	A159: Selective reporting (reporting bias)	Low	Outcome data reported.
WV15708	A159: Other bias	Unclear	Placebo contents and colour and similarity to acti could not analyze for primary outcome of efficacy
WV15708	A159: Blinding of participants and personnel (performance bias)	Low	
WV15708	All outcomes	Low	

WV15708	A159: Blinding of outcome assessment (detection bias) All outcomes	Low	Outcome assessors were blind
WV15730	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating randomisations schedule not available
WV15730	Allocation concealment (selection bias)	Low	"Randomization was performed by a central randomisations service. The investigator telephoned the centre to report the subject's date number was then supplied by the randomisations
WV15730	Incomplete outcome data (attrition bias), symptoms	High	Available data analysed by ITTI population and not ITT
WV15730	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody production makes the assessment of influenza status and associated complications in the infected subpopulation non-comparable between the treatment groups
WV15730	Incomplete outcome data (attrition bias), safety data	Low	Based on all randomised participants
WV15730	Selective reporting (reporting bias), other bias	High	Outcomes of primary interest for the ITT population not made available to the review auth
WV15730	Other bias	High	Placebo capsule contained dehydrocholic acid
WV15730	Blinding of participants and personnel (performance bias), all outcomes	Low	Matching placebo.
WV15730	Blinding of outcome assessment (detection bias), all outcomes	Low	"No open key to the code was available at the study centre, to the monitors, statistician or at Roche Headquarters. In the event of a medical emergency the blinding was to be broken if considered absolutely mandatory to properly manage the patient
WV15758	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating randomisations schedule not available
WV15758	Allocation concealment (selection bias)	Low	"Randomization was conducted by a central randomisations service, ICTI (Interactive

			Clinical Technologies Inc., Princeton, NJ). The investigator telephoned the centre to report the subject's date of birth, sex, a centre in the form of a message on an interactive response system (IVRS). The investigator entered the randomisations number in the appropriate place on the case report form. The subject randomisations numbers were allocated sequentially within a stratum in the order in which subjects were enrolled."
WV15758	Incomplete outcome data (attrition bias), symptoms	Low	Data available for both influenza infected and non-infected study populations
WV15758	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody production makes the assessment of influenza status and associated complications in the infected subpopulation non-comparable be
WV15758	Incomplete outcome data (attrition bias), safety data	Low	Based on all randomized patients
WV15758	Selective reporting (reporting bias), other bias	Low	Outcomes of primary interest to the review for ITT population available in the CONSORT-based extraction reconstruction
WV15758	Other bias	Unclear	Unable to ascertain placebo capsule contents
WV15758	Blinding of participants and personnel (performance bias), all outcomes	Low	"No open key to the code was available at the study centre..."
WV15758	Blinding of outcome assessment (detection bias), all outcomes	Low	"No open key to the code was available (...) to the Roche monitors, statisticians or at Roche Headquarters."
WV15759	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating randomisations schedule not available
WV15759	Allocation concealment (selection bias)	Low	The subject randomizations numbers will be generated by Roche or its designee and incorp Randomization will be conducted by a central randomization service by telephone.
WV15759	Incomplete outcome data (attrition bias), symptoms	Unclear	Insufficient information was available to ascertair populations for analysis and judge risk of bias

WV15759 WV15871	Incomplete outcome data (attrition bias), complications of influenza	Unclear	Insufficient information was available to ascertain populations for analysis and judge risk of bias
WV15759 WV15871	Incomplete outcome data (attrition bias), safety data	Unclear	Insufficient information was available to ascertain populations for analysis and judge risk of bias
WV15759 WV15871	Selective reporting (reporting bias), other bias	High	No outcome data were provided in the study CONSORT-based extraction reconstruction
WV15759 WV15871	Other bias	High	Placebo capsule contained dehydrocholic acid
WV15759 WV15871	Blinding of participants and personnel (performance bias), all outcomes	Low	Matching placebo
WV15759 WV15871	Blinding of outcome assessment (detection bias), all outcomes	Unclear	Inadequate information available to ascertain whether outcome assessors were aware of treatment group assignment
WV15799	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating randomisations schedule not available
WV15799	Allocation concealment (selection bias)	Unclear	Inadequate information available to ascertain concealment of allocation
WV15799	Incomplete outcome data (attrition bias), symptoms	Low	Not applicable to the study design (prophylaxis)
WV15799	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody production makes the assessment of influenza status and associated complications in the infected subpopulation non-comparable between the treatment groups
WV15799	Incomplete outcome data (attrition bias), safety data	Low	Based on all randomised participants
WV15799	Selective reporting (reporting bias), other bias	High	Outcome data for ITT population were not available to the review authors

WV15799	Other bias	Unclear	No information available on placebo contents
WV15799	Blinding of participants and personnel (performance bias), all outcomes	Unclear	Inadequate information available to ascertain presentation of placebo capsules
WV15799	Blinding of outcome assessment (detection bias), all outcomes	Unclear	Inadequate information available to ascertain whether outcome assessors were aware of treatment group assignment
WV15812	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating r
WV15812			"The randomisation numbers were generated by inc., Princeton, NJ, USA)."
WV15872	Allocation concealment (selection bias)	Low	"The investigator telephoned the centre to report The randomization number was then supplied by system (IVRS). The investigator entered the rand
WV15812	Incomplete outcome data (attrition bias), symptoms	High	Available data analyzed by ITTI population and no
WV15812	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody product complications in the infected subpopulation non-
WV15812	Incomplete outcome data (attrition bias), safety data	Low	Based on all participants irrespective of complian
WV15812	Selective reporting (reporting bias), other bias	High	Outcomes of primary interest for the ITT populati
WV15872	Other bias	Unclear	Placebo contained dehydrocholic acid. Dosage no
WV15812	Blinding of participants and personnel (performance bias), all outcomes	Low	Matching placebo described
WV1581	Blinding of outcome	Unclear	Inadequate information available to ascertain wh

2 WV15872 WV15819 WV15876 WV15978 WV15819 WV15876 WV15978 WV15819 WV15876 WV15978 WV15819 WV15876 WV15978 WV15819 WV15876 WV15978 WV15819	assessment (detection bias), all outcomes		of treatment group assignment
	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating randomisations schedule not available
	Allocation concealment (selection bias)	Low	"Randomization was conducted by a central randomisations service via telephone. The investigator or study coordinator telephoned vaccination status and history of COAD, and the tr number was then supplied by the centre. The ran in the appropriate place on the subject's Case Rep
	Incomplete outcome data (attrition bias), symptoms	Low	Available data analysed for both by ITTI and ITT populations
	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody production makes the assessment of influenza status and associated complications in the infected subpopulation non-comparable between the treatment groups
	Incomplete outcome data (attrition bias), safety data	Low	Based on all randomised participants
	Selective reporting (reporting bias), other bias	Low	Outcomes of primary interest to the review are available in the CONSORT-based extraction reconstruction
	Other bias	High	Placebo capsule contained dehydrocholic acid

8			
WV15819			
WV15876	Blinding of participants and personnel		
WV15978	(performance bias), all outcomes	Low	Matching placebo described
WV15819			
WV15876	Blinding of outcome		“No open key to the code was available at the study centres, to the monitors, statisticians or at Roche headquarters. In the event of a medic
WV15978	assessment (detection bias), all outcomes	Low	mandatory to properly manage the subject, by co the randomisations centre.”
WV15825	Random sequence generation (selection bias)	Unclear	Described as randomised; procedure generating r
WV15825	Allocation concealment (selection bias)	Unclear	Inadequate information available to ascertain con
WV15825	Incomplete outcome data (attrition bias), symptoms	Low	Not applicable to the study design (prophylaxis)
WV15825	Incomplete outcome data (attrition bias), complications of influenza	High	Possible effect of oseltamivir on antibody product complications in the infected subpopulation non-c
WV15825	Incomplete outcome data (attrition bias), safety data	Low	Based on all randomised participants
WV15825	Selective reporting (reporting bias)	High	Outcome data relating to complications were not
WV15825	Other bias	Unclear	Placebo contained dehydrocholic acid. Dosage no
WV15825	Blinding of participants and personnel (performance bias), all outcomes	Unclear	
WV15825	Blinding of outcome assessment (detection bias), all outcomes	Unclear	